Lifeline Scientific, Inc Strategic review update (2652C)

TIDMLSIC

RNS Number : 2652C

Lifeline Scientific, Inc

27 June 2016

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

Strategic review update

Lifeline Scientific (AIM: LSIC), the transplantation technology company, provides the following update regarding its strategic review as last discussed in its preliminary results announcement of 29 April, 2016. While the final outcome of its strategic review has not yet been reached, the Board can confirm that discussions continue with interested parties. These discussions may or may not lead to an offer for the Company and no assurances can be made as to the outcome of these discussions. The Board intends to update the market upon its decision regarding the outcome of the strategic review in due course.

The prospects for Lifeline Scientific remain solid for 2016, with trading-to date significantly ahead of the same period last year. Lifeline will provide a trading update on first half results during August 2016.

For further information:

 
 Lifeline Scientific,          www.lifeline-scientific.com 
  Inc. 
 David Kravitz, CEO                   Tel: [phone] 
 Lisa Kieres, CFO                     Tel: [phone] 
 
 Panmure Gordon (UK)              Tel: [phone] 
  Limited 
 Freddy Crossley (Corporate 
  Finance) 
 Tom Salvesen (Corporate 
  Broking) 
 
 Walbrook PR Limited          Tel: [phone] or 
                                   [e-mail] 
 Paul McManus                     Mob: [phone] 
 Lianne Cawthorne                 Mob: [phone] 
 

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of donor kidneys. Employed by surgeons in over 218 leading transplant programmes in 32 countries, LifePorts have successfully preserved more than 70,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com

About LifePort Liver Transporter

LifePort Liver Transporter is modelled upon the clinically proven technology platform of LifePort Kidney Transporter and the Company's early HMP prototype successfully used in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol(R), are in the process of US and international regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specialising in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCAKQDNPBKDOAB

(END) Dow Jones Newswires

June 27, 2016 02:00 ET (06:00 GMT)